MAX HEALTHCARE: Strong Q2 Growth; 7,500+ Beds Planned

Max Healthcare Institute Limited reported healthy operating performance in Q2 FY27, supported by revenue growth, stable margins and continued expansion across its healthcare network. 📊 Q2 & H1 FY27 – Key Highlights Q2 Revenue: ₹3,055 Cr, up 18% YoY Q2 Operating EBITDA: ₹820 Cr EBITDA Margin: 26.8% Q2 PAT: ₹448 Cr H1 Revenue: ₹5,890 Cr, up 17% YoY H1 Operating EBITDA: ₹1,524 Cr, up 17% YoY H1 PAT: ₹805 Cr Operating Free Cash Flow: ₹500 Cr in Q2 🚀 Expansion & Growth Strategy Plans to add 7,500+ beds over the next five years. Expansion through brownfield projects, greenfield hospitals, built-to-suit models and acquisitions. Max Lab has expanded its presence across 60+ cities. Max@Home records 5,000+ daily billed transactions. Max MyHealth digital platform has crossed 21 lakh patient registrations. 📌 Balance Sheet Snapshot Gross Debt: ₹3,233 Cr Cash & Bank Balances: ₹1,074 Cr Shareholders' Equity: ₹12,738 Cr Investor Insight: Max Healthcare's performance reflects healthy revenue growth and operating profitability. Its ambitious capacity expansion and growing asset-light healthcare businesses provide additional long-term growth opportunities. However, execution of the expansion pipeline, capital expenditure requirements and returns from new beds will remain important factors to monitor. Disclaimer: For educational and informational purposes only. Not investment advice. Like | Share | Follow for more market insights. MAXHEALTH